Eating Disorders and GLP-1 RAs

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications
originally developed to treat type 2 diabetes. GLP-1 RAs are now being used as an approved or off-label treatment for weight loss and have been trialled as a treatment for some eating disorders such as binge eating disorder (BED).

There is limited research available to help researchers, clinicians and patients/consumers to understand 
the relationships between GLP-1 RAs and eating disorders. However, it is thought that GLP-1 RAs may 
negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information about GLP-1 RAs as well as their possible interaction with eating disorders including physical and psychological impacts. Practice points are provided for clinicians.


« Back to Browse Resources

See also

EDNA Information Sheet - Carers

This information sheet has been developed by Eating Disorders Neurodiversity Australia.

Read more

Issue 60 I Eating Disorders in Aged Care: What does this look like?

NEDC e-Bulletin Editor’s Note Welcome to the 60th edition of the NEDC e-Bulletin.

Read more

Stepped System of Care - Greek

Η National Eating Disorders Collaboration (NEDC) έχει ενσωματώσει δύο δεκαετίες συναίνεσης τομεακών και βιωμένων εμπειριών και ανάπτυξης υπηρεσιών στο μοντέλο του σταδιακού συστήματος περίθαλψης για τις διατροφικές διαταχές (Εικόνα 1η).

Read more

Consumer checklist (Wade et al.)

Getting treatment for an eating disorder can be a daunting process given that most people know little about eating disorders and effective treatments.

Read more